Statin use before and after the KDIGO Lipids in chronic kidney disease guideline: A population‐based interrupted time series analysis
Open Access
- 16 July 2022
- journal article
- research article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 131 (5) , 306-310
Abstract
In November 2013, the Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease was published, recommending statins for all individuals 50 years or older with an estimated glomerular filtration rate below 60 ml/min/1.73 m2 to lower the risk of major cardiovascular events. We quantified the prevalence of statin use among the target population before and after the guideline publication in a large Danish cohort of individuals with an estimated glomerular filtration rate below 60 ml/min/1.73 m2, to investigate the effect of the guideline, but found no difference in the prevalence of statin use prior to and after the guideline publication.Keywords
This publication has 19 references indexed in Scilit:
- Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription ratesKidney International, 2015
- Cardiac and Kidney Markers for Cardiovascular Prediction in Individuals With Chronic Kidney DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2014
- Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled TrialsThe American Journal of Cardiology, 2014
- Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice GuidelineAnnals of Internal Medicine, 2014
- Statins of high versus low cholesterol‐lowering efficacy and the development of severe renal failurePharmacoepidemiology and Drug Safety, 2013
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialThe Lancet, 2011
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisNew England Journal of Medicine, 2009
- Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing HemodialysisNew England Journal of Medicine, 2005
- The Epidemiologist's Dream: DenmarkScience, 2003
- Segmented regression analysis of interrupted time series studies in medication use researchJournal of Clinical Pharmacy and Therapeutics, 2002